Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 8/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21535643 | 1.00 | PIK3CD (0.48) | PIK3CDGPR119ABHD6USP30PIK3CA | |
| SCHEMBL2775170 | 0.93 | GPR119 (0.54) | GPR119ABHD6 | |
| SCHEMBL30845436 | 0.91 | ABHD6 (0.50) | GPR119ABHD6USP30 | |
| SCHEMBL29686325 | 0.87 | PIK3CD (0.49) | PIK3CDGPR119USP30PIK3CAPIK3CB | |
| SCHEMBL7466564 | 0.87 | PIK3CD (0.49) | PIK3CDGPR119USP30PIK3CAPIK3CB | |
| SCHEMBL22278273 | 0.87 | GPR119 (0.52) | PIK3CDGPR119USP30PIK3CAPIK3CB | |
| SCHEMBL22278189 | 0.87 | GPR119 (0.52) | PIK3CDGPR119USP30PIK3CAPIK3CB | |
| SCHEMBL22278188 | 0.87 | GPR119 (0.52) | PIK3CDGPR119USP30PIK3CAPIK3CB | |
| SCHEMBL14778459 | 0.86 | PIK3CD (0.48) | PIK3CDGPR119USP30PIK3CAPIK3CB | |
| SCHEMBL7463050 | 0.86 | PIK3CD (0.48) | PIK3CDGPR119USP30PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4144735-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-3523302-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | PIK3CD 1807/4885GPR119 1905/4885ABHD6 4842/4885 |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | PIK3CD 1807/4885GPR119 1905/4885ABHD6 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.